Dr. James Shannon Joins myTomorrows Supervisory Board

News provided by

Jan 11, 2016, 08:00 ET

AMSTERDAM, January 11, 2016 /PRNewswire/ --

myTomorrows (Amsterdam, the Netherlands) today announced that Dr. James Shannon will join its supervisory board, effective immediately.

"James' decades of drug development leadership and forward thinking vision will add a valuable perspective to our mission. His views on effectiveness vs efficacy, rational pharmacotherapy and data driven treatment decision making will help propel us faster towards our company's promise to doctors, patients and drug developers. We look forward to benefitting from his judgment and counsel." Ronald Brus, Founder & CEO myTomorrows

Dr. James Shannon retired from GlaxoSmithKline as Chief Medical Officer in April 2015. Trained in Medicine and Cardiology, Dr. Shannon is a member of the Royal College of Physicians. Previously Dr. Shannon had a long career serving in various senior positions with Sterling Winthrop, Sandoz and Novartis and in 2005 he was appointed Global Head Pharma Development at Novartis. Dr. Shannon currently also serves on the boards of Mannkind Corporation and Immodulon.

"myTomorrows has proven its model works. We owe it to all doctors and patients around the world facing significant unmet medical needs to have access as early as possible to effective drugs, empowering them with data, information, decision-making tools, and actual access to drugs in development. In today's rapidly connecting society, developing a drug without fully engaging the informed patient and physician will become a thing of the past." Dr. James Shannon

About myTomorrows

myTomorrows provides services to patients and physicians in need of drugs in development and diagnostic tests. Through its Internet-based platform, myTomorrows provides uniform public information about early access programs, clinical trials and diagnostic tests to enhance data-driven decision-making and enable rational pharmacotherapy. myTomorrows also facilitates requests for diagnostic tests and drugs in development. For more information about myTomorrows, please visit http://www.mytomorrows.com.

Contact: Erdem Yavuz, [email protected], +31-88-525-3888

SOURCE myTomorrows